# Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

> **NCT05201729** · — · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma, PDAC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05201729
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201729, "Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05201729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*